The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
This first extensive Middle Eastern and South Asian cohort reported a higher-than-previously known incidence of IREs. Hypothyroidism, insulin deficiency, and hyperthyroidism were the commonest IREs, with pembrolizumab being the commonest ICI. IRE development was associated with higher age, a low WBC count, pembrolizumab, and nivolumab use. The development of IREs did not seem to influence mortality. Further research on IREs is imperative to optimize management guidelines in the era of precision medicine.
Authors
- Fateen Ata (ORCID: https://orcid.org/0000-0001-7121-8574)
- Amr Faisal Musaed Alsharafi
- Mohammad Nofal (ORCID: https://orcid.org/0000-0003-4248-5387)
- Loai Abdullah (ORCID: https://orcid.org/0009-0005-3092-3345)
- Kakil Ibrahim Rasul (ORCID: https://orcid.org/0000-0002-5609-6246)
- Haval Surchi (ORCID: https://orcid.org/0009-0008-2786-9650)
- Adeel Ahmad Khan (ORCID: https://orcid.org/0000-0003-1583-1539)
- Ayman R. Ibrahim (ORCID: https://orcid.org/0000-0003-3458-1475)
- Reham Abo Shdid
- Tareq Al-Bkoor (ORCID: https://orcid.org/0009-0004-9475-9487)
- Emad Algorani
- Kofi Annan (ORCID: https://orcid.org/0009-0003-9693-8844)
- Tarik Abdelkareim Elhadd (ORCID: https://orcid.org/0000-0003-3451-503X)
Institutions
- Hamad General Hospital (QA)
- National Center for Cancer Care and Research (QA)
- Hamad Medical Corporation (QA)
Publication Details
- Journal
- BMC Medicine
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12916-024-03812-2
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Hamad Medical Corporation